Health
Affinity’s COVID-19 antibodies ready for manufacture for clinical trials – BSA bureau
The study offers a roadmap for speeding development of Monoclonal Antibodies for other diseases; Techniques applied to COVID-19 studies completed Phase 1 Trial
The study offers a roadmap for speeding development of Monoclonal Antibodies for other diseases; Techniques applied to COVID-19 studies completed Phase 1 Trial
Tychan, a Singapore-based clinical-stage biotechnology company focused on developing life-saving treatments through disruptive technologies, announced on 30 July 2020 a publication in New England Journal of Medicine (NEJM) demonstrating the safety and efficacy for TY014, a novel monoclonal antibody candidate treatment for yellow fever (Y…
-
General15 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
Noosa News21 hours agoPerth Royal Show vendors upset by price hikes, say crowds are down in 2025
-
Business23 hours agoBell Potter names the best ASX shares to buy in October
-
General20 hours agoAustralia welcomes Gaza peace progress, hostage release